Featured Publications
Trajectories of relapse in randomised, placebo-controlled trials of treatment discontinuation in major depressive disorder: an individual patient-level data meta-analysis
Gueorguieva R, Chekroud AM, Krystal JH. Trajectories of relapse in randomised, placebo-controlled trials of treatment discontinuation in major depressive disorder: an individual patient-level data meta-analysis. The Lancet Psychiatry 2017, 4: 230-237. PMID: 28189575, PMCID: PMC5340978, DOI: 10.1016/s2215-0366(17)30038-x.Peer-Reviewed Original ResearchConceptsActive medicationActive treatmentClinical trialsDepression severityHamilton Depression Rating Scale scoresDepression Rating Scale scoresClinical Global Impression scoresIndividual patient-level dataDouble-blind treatmentPlacebo-controlled trialPatterns of relapseGlobal Impression scoresIndividual patient dataPrevention of relapseTrajectory class membershipTreatment of depressionMajor depressive disorderRating Scale scoresPatient-level dataPost-traumatic stress disorderTreatment discontinuationAntidepressant treatmentClinical responseAlcohol Research CenterAntidepressant medicationCross-trial prediction of treatment outcome in depression: a machine learning approach
Chekroud AM, Zotti RJ, Shehzad Z, Gueorguieva R, Johnson MK, Trivedi MH, Cannon TD, Krystal JH, Corlett PR. Cross-trial prediction of treatment outcome in depression: a machine learning approach. The Lancet Psychiatry 2016, 3: 243-250. PMID: 26803397, DOI: 10.1016/s2215-0366(15)00471-x.Peer-Reviewed Original ResearchConceptsTreatment outcomesTreatment groupsEscitalopram treatment groupSpecific antidepressantsPatient-reported dataSequenced Treatment AlternativesClinical trial dataIndependent clinical trialsClinical remissionSymptomatic remissionClinical trialsTreatment efficacyPatientsProspective identificationTreatment alternativesTrial dataDepressionRemissionAntidepressantsOutcomesGroupLevel 1CitalopramCohortClinicians
2024
Smartband-based smoking detection and real-time brief mindfulness intervention: findings from a feasibility clinical trial
Horvath M, Pittman B, O’Malley S, Grutman A, Khan N, Gueorguieva R, Brewer J, Garrison K. Smartband-based smoking detection and real-time brief mindfulness intervention: findings from a feasibility clinical trial. Annals Of Medicine 2024, 56: 2352803. PMID: 38823419, PMCID: PMC11146247, DOI: 10.1080/07853890.2024.2352803.Peer-Reviewed Original ResearchConceptsBrief mindfulness interventionsMindfulness exercisesTreatment startersMindfulness interventionSmoking interventionsOnline mindfulness trainingWhite non-HispanicMindfulness trainingTreatment fidelityFeasibility measuresHelpfulness ratingsNon-HispanicDaily smokersPredicting smokingReduce smokingExerciseSmokingCigarette smokingInterventionLow completenessAdherenceParticipantsSmartbandAcceptanceMindfulness
2023
Naltrexone plus bupropion combination medication maintenance treatment for binge-eating disorder following successful acute treatments: randomized double-blind placebo-controlled trial
Grilo C, Lydecker J, Gueorguieva R. Naltrexone plus bupropion combination medication maintenance treatment for binge-eating disorder following successful acute treatments: randomized double-blind placebo-controlled trial. Psychological Medicine 2023, 53: 7775-7784. PMID: 37366017, PMCID: PMC10751383, DOI: 10.1017/s0033291723001800.Peer-Reviewed Original ResearchConceptsNaltrexone/bupropionBinge-eating disorderBinge-eating remissionAcute treatmentMaintenance treatmentBinge-eating frequencyDouble-blind placebo-controlled trialBehavioral weight loss therapyWeight lossCo-occurring obesitySuccessful acute treatmentPlacebo-controlled trialWeight loss therapySignificant additional weight lossSingle-site trialAdditional weight lossAcute efficacyRemission rateAdult patientsComorbid obesityBupropionInitial interventionPosttreatment assessmentRespondersPlaceboCognitive‐behavioral therapy for binge‐eating disorder for non‐responders to initial acute treatments: Randomized controlled trial
Grilo C, Lydecker J, Gueorguieva R. Cognitive‐behavioral therapy for binge‐eating disorder for non‐responders to initial acute treatments: Randomized controlled trial. International Journal Of Eating Disorders 2023, 56: 1544-1553. PMID: 37144325, PMCID: PMC10524840, DOI: 10.1002/eat.23975.Peer-Reviewed Original ResearchConceptsInitial acute treatmentBinge-eating disorderCognitive behavioral therapyAcute treatmentBinge-eating frequencyInitial interventionTherapist-led cognitive behavioural therapyInitial pharmacological treatmentTreat remission ratesEvidence-based treatmentsSingle-site trialAcute efficacyRemission rateAdult patientsInitial treatmentPharmacological treatmentPatientsPosttreatment assessmentBehavioral treatmentSufficient benefitTherapyDisordersInterventionTreatmentPharmacotherapy
2022
Naltrexone-Bupropion and Behavior Therapy, Alone and Combined, for Binge-Eating Disorder: Randomized Double-Blind Placebo-Controlled Trial
Grilo CM, Lydecker JA, Fineberg SK, Moreno JO, Ivezaj V, Gueorguieva R. Naltrexone-Bupropion and Behavior Therapy, Alone and Combined, for Binge-Eating Disorder: Randomized Double-Blind Placebo-Controlled Trial. American Journal Of Psychiatry 2022, 179: 927-937. PMID: 36285406, PMCID: PMC9722598, DOI: 10.1176/appi.ajp.20220267.Peer-Reviewed Original ResearchConceptsBehavioral weight loss therapyBinge-eating disorderPlacebo groupBupropion groupWeight lossRandomized double-blind placebo-controlled trialDouble-blind placebo-controlled trialLogistic regressionBinge-eating remissionPlacebo-controlled trialWeight loss therapyDouble-blind placeboSerious public health problemPublic health problemEvidence-based treatmentsRate of participantsBinge-eating frequencyBinge Eating DisorderMedical comorbiditiesRemission rateLoss therapyPercent weight lossMixed modelsFunctional impairmentSecondary measuresJoint longitudinal trajectories of pain intensity and opioid prescription in veterans with back pain
Buta E, Gordon KS, Gueorguieva R, Becker WC, Heapy A, Bathulapalli H, Zeng Q, Redd D, Brandt C, Goulet J. Joint longitudinal trajectories of pain intensity and opioid prescription in veterans with back pain. Pharmacoepidemiology And Drug Safety 2022, 31: 1262-1271. PMID: 35996825, DOI: 10.1002/pds.5531.Peer-Reviewed Original ResearchConceptsBack painOpioid prescriptionsPain/Pain intensityRetrospective cohort studyTrajectories of painElectronic health record dataMental health diagnosesHealth record dataHigh opioidCohort studyClinical predictorsHigher oddsPainLatent class growth analysisOpioidsPain classesHealth diagnosisRecord dataVeteransLongitudinal trajectoriesPrescriptionOddsTrajectory classesDistinct patterns
2021
Randomized Controlled Trial of Treatments for Loss‐of‐Control Eating Following Bariatric Surgery
Grilo CM, Ivezaj V, Duffy AJ, Gueorguieva R. Randomized Controlled Trial of Treatments for Loss‐of‐Control Eating Following Bariatric Surgery. Obesity 2021, 29: 689-697. PMID: 33694287, PMCID: PMC7995173, DOI: 10.1002/oby.23124.Peer-Reviewed Original ResearchConceptsBariatric surgeryWeight lossAllied health cliniciansBariatric surgery outcomesThree-month treatmentSelf-help treatmentBariatric surgery settingsSignificant differencesControlled TrialsSurgery settingSurgery outcomesTreatment outcomesHealth cliniciansPosttreatment outcomesNon-White participantsControl eatingSurgeryTrialsOutcomesTreatmentPatientsCategorical outcomesWhite participantsAbstinenceHigher proportion
2020
Examining Self-Weighing Behaviors and Associated Features and Treatment Outcomes in Patients with Binge-Eating Disorder and Obesity with and without Food Addiction
Wiedemann AA, Ivezaj V, Gueorguieva R, Potenza MN, Grilo CM. Examining Self-Weighing Behaviors and Associated Features and Treatment Outcomes in Patients with Binge-Eating Disorder and Obesity with and without Food Addiction. Nutrients 2020, 13: 29. PMID: 33374870, PMCID: PMC7823454, DOI: 10.3390/nu13010029.Peer-Reviewed Original ResearchConceptsBinge-eating disorderFood addictionFrequency of weighingShape/weightRelated perceptionsEating Disorder ExaminationBinge Eating DisorderBehavioral weight loss treatmentWeight loss treatmentDisorder ExaminationLess acceptanceFrequent weighingPoor treatment outcomesTreatment outcomesNegative reactionsBWL treatmentParticipantsLoss treatmentMixed effects modelsPerceptionFA statusAddictionAssociated featuresGreater likelihoodIndividualsNaltrexone + Bupropion Combination for the Treatment of Binge-eating Disorder with Obesity: A Randomized, Controlled Pilot Study
Grilo CM, Lydecker JA, Morgan PT, Gueorguieva R. Naltrexone + Bupropion Combination for the Treatment of Binge-eating Disorder with Obesity: A Randomized, Controlled Pilot Study. Clinical Therapeutics 2020, 43: 112-122.e1. PMID: 33218742, PMCID: PMC7902424, DOI: 10.1016/j.clinthera.2020.10.010.Peer-Reviewed Original ResearchConceptsBinge-eating disorderEating-disorder psychopathologyPilot RCTTreatment of BEDOutcome time pointDouble-blind treatmentPercentage of patientsControlled Pilot StudyDiscontinuation of medicationTreatment of bingeEvidence-based treatmentsBinge-eating frequencyBupropion combinationAdult patientsAdverse eventsComorbid obesitySecondary outcomesPrimary outcomeAcute effectsFunctional impairmentPlaceboLong-term effectsPatientsMost outcomesObesityRandomized Controlled Trial of Behavioral Weight Loss and Stepped Care for Binge‐Eating Disorder: 12‐Month Follow‐up
Grilo CM, White MA, Ivezaj V, Gueorguieva R. Randomized Controlled Trial of Behavioral Weight Loss and Stepped Care for Binge‐Eating Disorder: 12‐Month Follow‐up. Obesity 2020, 28: 2116-2124. PMID: 32985114, PMCID: PMC7644623, DOI: 10.1002/oby.22975.Peer-Reviewed Original ResearchConceptsBehavioral weight lossStepped careWeight lossWeight loss medicationsRandomized Controlled TrialsSignificant weight lossBinge-eating disorderBinge-eating frequencySignificant time effectBinge Eating DisorderCognitive behavioral therapyRemission rateControlled TrialsTreatment respondersLong-term effectsBehavioral therapyMixed modelsPatientsCareObesitySignificant reductionTreatmentMonthsPosttreatmentDisordersProspective association of e‐cigarette and cigarette use with alcohol use in two waves of the Population Assessment of Tobacco and Health
Roberts W, Verplaetse T, Peltier MKR, Moore KE, Gueorguieva R, McKee SA. Prospective association of e‐cigarette and cigarette use with alcohol use in two waves of the Population Assessment of Tobacco and Health. Addiction 2020, 115: 1571-1579. PMID: 31977106, PMCID: PMC7340560, DOI: 10.1111/add.14980.Peer-Reviewed Original ResearchConceptsAlcohol use outcomesHazardous alcohol useE-cigarette useE-cigarettesCigarette useAlcohol useUse outcomesExposure groupCigarette usersTotal drinksSocio-demographic risk factorsUnited States adult populationWave 1Non-institutionalized adultsStates adult populationHarmful alcohol consumptionNon-daily useE-cigarette usersPoorer alcohol use outcomesSocio-demographic characteristicsRisk factorsHealth SurveyHigher oddsTobacco cigarettesAlcohol abuseRandomized Controlled Trial Testing the Effectiveness of Adaptive “SMART” Stepped-Care Treatment for Adults With Binge-Eating Disorder Comorbid With Obesity
Grilo CM, White MA, Masheb RM, Ivezaj V, Morgan PT, Gueorguieva R. Randomized Controlled Trial Testing the Effectiveness of Adaptive “SMART” Stepped-Care Treatment for Adults With Binge-Eating Disorder Comorbid With Obesity. American Psychologist 2020, 75: 204-218. PMID: 32052995, PMCID: PMC7027689, DOI: 10.1037/amp0000534.Peer-Reviewed Original ResearchConceptsStepped-care treatmentCognitive behavioral therapyWeight loss medicationsBinge-eating disorderStepped careRemission rateWeight lossBehavioral weight lossSignificant weight lossBinge-eating frequencySignificant time effectControlled TrialsTreat analysisTreatment respondersMedicationsPlaceboMixed model analysisClinical practiceNonrespondersPatientsObesityBinge eatingCareMonthsTreatment
2019
The Association of Impulsivity and Family History of Alcohol Use Disorder on Alcohol Use and Consequences
Haeny AM, Gueorguieva R, Morean ME, Krishnan‐Sarin S, DeMartini KS, Pearlson GD, Anticevic A, Krystal JH, O'Malley SS. The Association of Impulsivity and Family History of Alcohol Use Disorder on Alcohol Use and Consequences. Alcohol Clinical And Experimental Research 2019, 44: 159-167. PMID: 31693193, PMCID: PMC6981005, DOI: 10.1111/acer.14230.Peer-Reviewed Original ResearchConceptsFacets of impulsivityBarratt Impulsiveness ScaleAlcohol-related problemsAlcohol use disorderProblem drinkingAssociation of impulsivityImpulsivity-related traitsAlcohol-related consequencesUse disordersFHP individualsAlcohol outcomesImpulsiveness ScaleImpulsivityProblematic drinkingFHN individualsDrinking quantityAlcohol quantityTranslational neuroscienceAlcohol misuseAlcohol useTransdisciplinary Tobacco Use Research CenterMain effectAnalysis of covariancePhenotypic riskStrong positive associationHistopathology‐guided mass spectrometry differentiates benign nevi from malignant melanoma
Lazova R, Smoot K, Anderson H, Powell MJ, Rosenberg AS, Rongioletti F, Pilloni L, D'Hallewin S, Gueorguieva R, Tantcheva‐Poór I, Obadofin O, Camacho C, Hsi A, Kluger HH, Fadare O, Seeley EH. Histopathology‐guided mass spectrometry differentiates benign nevi from malignant melanoma. Journal Of Cutaneous Pathology 2019, 47: 226-240. PMID: 31697431, DOI: 10.1111/cup.13610.Peer-Reviewed Original ResearchExamining sex as a predictor and moderator of treatment outcomes for binge‐eating disorder: Analysis of aggregated randomized controlled trials
Lydecker JA, Gueorguieva R, Masheb R, White MA, Grilo CM. Examining sex as a predictor and moderator of treatment outcomes for binge‐eating disorder: Analysis of aggregated randomized controlled trials. International Journal Of Eating Disorders 2019, 53: 20-30. PMID: 31497876, PMCID: PMC6983351, DOI: 10.1002/eat.23167.Peer-Reviewed Original ResearchConceptsBinge-eating disorderEating-disorder psychopathologyCognitive behavioral therapySelf-report measuresModerators of outcomeTreatment outcomesBehavioral weight lossStatistical Manual-Fourth EditionSignificant moderatorWeight lossControl conditionModeratorCourse of treatmentBetter treatment outcomesGreater weight lossMain effectStructured interviewsTreatment settingsPsychopathologyMultimodal treatmentPatient groupRCT studiesMedical CenterBed treatmentParticipantsImplementing Motivational Interviewing for Substance Misuse on Medical Inpatient Units: a Randomized Controlled Trial
Martino S, Zimbrean P, Forray A, Kaufman JS, Desan PH, Olmstead TA, Gilstad-Hayden K, Gueorguieva R, Yonkers KA. Implementing Motivational Interviewing for Substance Misuse on Medical Inpatient Units: a Randomized Controlled Trial. Journal Of General Internal Medicine 2019, 34: 2520-2529. PMID: 31468342, PMCID: PMC6848470, DOI: 10.1007/s11606-019-05257-3.Peer-Reviewed Original ResearchConceptsConsultation-liaison serviceSubstance misuseMotivational interviewMedical inpatientsGeneral medical inpatient servicesMedical inpatient servicesGeneral medical inpatientsStudy-eligible patientsMedical inpatient unitsAcute care hospitalsMain MeasuresPrimary outcomesMedical education workshopSecondary outcomesCare hospitalControlled TrialsEffective implementation strategiesMeasuresPrimary outcomesMedical HospitalInpatient unitInpatient servicesMedical ordersPatientsPatients' statementsMotivational interviewingInpatientsMaintenance of antidepressant and antisuicidal effects by D-cycloserine among patients with treatment-resistant depression who responded to low-dose ketamine infusion: a double-blind randomized placebo–control study
Chen MH, Cheng CM, Gueorguieva R, Lin WC, Li CT, Hong CJ, Tu PC, Bai YM, Tsai SJ, Krystal JH, Su TP. Maintenance of antidepressant and antisuicidal effects by D-cycloserine among patients with treatment-resistant depression who responded to low-dose ketamine infusion: a double-blind randomized placebo–control study. Neuropsychopharmacology 2019, 44: 2112-2118. PMID: 31421635, PMCID: PMC6898334, DOI: 10.1038/s41386-019-0480-y.Peer-Reviewed Original ResearchConceptsTreatment-resistant depressionAntisuicidal effectsPlacebo groupKetamine infusionDCS groupD-cycloserineDouble-blind randomized placebo-controlled studyN-methyl-D-aspartate (NMDA) glutamate receptorsHamilton Depression Rating Scale scoresLow-dose ketamine infusionRandomized placebo-controlled studyDepression Rating Scale scoresHAMD item 3Single subanesthetic doseInitial clinical responsePlacebo-controlled studyRating Scale scoresClinical responseDose titrationSubanesthetic doseAugmentation treatmentGlutamate receptorsMixed model analysisSuicidal riskScale scoreTobacco use increases risk of food insecurity: An analysis of continuous NHANES data from 1999 to 2014
Mayer M, Gueorguieva R, Ma X, White MA. Tobacco use increases risk of food insecurity: An analysis of continuous NHANES data from 1999 to 2014. Preventive Medicine 2019, 126: 105765. PMID: 31260724, DOI: 10.1016/j.ypmed.2019.105765.Peer-Reviewed Original ResearchConceptsLow food securityTobacco useTobacco productsNutrition Examination Survey dataSingle product useAlternative tobacco productsUse of cigarettesMagnitude of associationLogistic regression modelsMultiple tobacco productsMultinomial logistic regression modelsFood insecurityNational HealthHigh prevalenceHealth disparity issuesNHANES dataOnly cigarettesSignificant associationTobacco product typesProduct useHealth risksCigarettesAssociationRegression modelsOddsExamining Race as a Predictor and Moderator of Treatment Outcomes for Binge-Eating Disorder: Analysis of Aggregated Randomized Controlled Trials
Lydecker JA, Gueorguieva R, Masheb R, White MA, Grilo CM. Examining Race as a Predictor and Moderator of Treatment Outcomes for Binge-Eating Disorder: Analysis of Aggregated Randomized Controlled Trials. Journal Of Consulting And Clinical Psychology 2019, 87: 530-540. PMID: 31008634, PMCID: PMC6589831, DOI: 10.1037/ccp0000404.Peer-Reviewed Original ResearchConceptsBinge-eating disorderWhite participantsCognitive behavioral therapySelf-report measuresTreatment outcomesBinge-eating remissionModerate treatment outcomeBinge Eating DisorderBinge-eating episodesMain effectBlack participantsWeight lossBehavioral weight lossEvidence-based treatmentsLower depressionTreatment researchRandomized Controlled TrialsBetter treatment outcomesControl conditionParticipantsControlled TrialsMultimodal treatmentPercent weight lossPatient groupModerator